Company: CSCIF
Filing Date: 2025-04-09
Form Type: 20-F
Source: 0001641172-25-003456
Chunk: 88

Company: COSCIENS Biopharma Inc.
Filing Date: 2025-04-09
Form: 20-F
Item: Item 6
Chunk 88
---
 the Canadian Institute of
Corporate Directors.

Matthias Gerlachwas appointed as Managing
Director of Aeterna Zentaris GmbH in February 2024 and as Senior Vice President, Manufacturing and Supply Chain in January 2021.
From December 2011 through May 2014, he was our Vice President, Medicinal Chemistry. Dr. Gerlach, who is based in the Frankfurt office
of AEZS Germany, began his career in the pharmaceutical industry in 1997. He joined our Company in January 2001, assuming roles of increasing
responsibility in areas of medicinal chemistry and preclinical development through product commercialization during his career. He possesses
numerous scientific and business skills and has a long record of successful innovation, drug development and management, and contributed
significantly to the successful U. S.- and EU/UK-commercialization of macimorelin in the adult indication. Dr. Gerlach obtained a diploma
in Chemistry from the Johann Wolfgang Goethe University in Frankfurt in 1994 and was awarded his doctorate diploma in synthetic organic
chemistry by the Johann Wolfgang Goethe University in 1997.

  63  

Dr. Ulrich Kosciessaserves as a director
on our board. Dr. Kosciessa currently serves as the Chief Executive Officer of Germany-based Photonamic GmbH & Co. KG and as the
Chief Operating Officer of Tokyo-based SBI Pharmaceuticals Co. LTD. He has worked for 20 years for Medac GmbH, a global pharmaceutical
company with operations in 70 countries where he served as a member of the Executive Management Board, as Managing Director of Medac
International and as Chairman of the Board of Medac Pharma Inc., a U. S.-based subsidiary of Medac GmbH focused on specialty pharmaceuticals
for autoimmune diseases and cancer. Throughout his career at Medac, Dr. Kosciessa has formed several subsidiaries and affiliates as well
as established a network of global partners, growing the Company’s international business more than 50% since 2005. In addition, since
2006 Dr. Kosciessa has also served as Chief Executive Officer of Photonamic, a subsidiary of Medac GmbH focused on research and development
of photodynamic therapy and diagnostics. He has successfully developed two Photonamic products currently marketed in Europe, North America,
South America, the Asian Pacific region and Australia. From 2006 to 2008, Dr. Kosciessa served as Chief Executive Officer at Immune Laboratory
of Hannover